Episode 31: Dr. Thomas Cahill

Dr. Thomas Cahill is trying to change how medicine gets built, funded, priced, and delivered.

In this episode of The Disruptors, Dr. Cahill shares how he went from MD-PhD student at Duke to founding Newpath Partners, why transformative medicine requires more than scientific discovery, and how genomics, cost, prevention, patient data, and better incentives could reshape the future of healthcare.

Dr. Thomas Cahill did not originally set out to run an investment fund.

He was an MD-PhD student at Duke, investing, learning, and helping build companies while still in training. His expected path was academic medicine: becoming an assistant professor, continuing in research, and staying inside the traditional scientific system.

Then someone made a very unusual bet on him.

As a medical student, Cahill was given the opportunity to manage $100 million and build something different. That became Newpath Partners, a life sciences investment firm focused on building companies around transformative medicines, not incremental improvements or “me too” assets.

For Cahill, the goal is not simply to invest in biotech. The goal is to identify major scientific shifts before they become obvious and help turn them into companies that can actually reach patients.

He describes science as moving through punctuated equilibrium. For long periods, progress can appear steady. Then, suddenly, a field changes. GLP-1 drugs, gene sequencing, and new therapeutic platforms are examples of those moments when science moves from one era into another.

The conversation begins with one of Cahill’s biggest beliefs: weight is one of the most important factors connected to lifespan.

He argues that weight is a major driver of mortality, heart disease, stroke, diabetes, inflammation, and broader health outcomes. During COVID, he says, weight was one of the most important correlated risk factors, and he believes wider access to GLP-1 medicines such as Wegovy, Ozempic, and related drugs could have had a major effect on outcomes.

But Cahill’s point is broader than weight loss.

He sees GLP-1 drugs as part of a larger shift in medicine: therapies that do not just treat one endpoint, but create secondary effects across inflammation, fertility, metabolic health, eating behavior, and long-term disease risk. In his view, these drugs represent the kind of scientific shift that can change the healthcare system if access and cost are solved.

Cost is one of the central themes of the episode.

Cahill argues that an expensive drug saves no one if it cannot be distributed. A therapy may be scientifically successful, but if it costs millions of dollars and cannot reach patients, the system has failed. He believes healthcare innovation has to include not only better science, but also better manufacturing, logistics, pricing, and access.

That perspective is one of the ways he separates Newpath’s approach from traditional biotech investing.

In biotech, many companies do not have revenue for years. They depend on capital, clinical trial progress, future approvals, and investor conviction. Cahill explains that this makes biotech difficult for public markets and generalist investors, because the companies can be hard to value and easy to misprice.

For him, the answer is not hype. It is building companies with a real path to patients, a real understanding of cost, and a real chance to create medicines that can be used at scale.

The episode also goes deep into genomics and whole genome sequencing.

Cahill believes that everyone should have access to their own genetic data and medical records. He explains that whole genome sequencing can reveal disease risks, inherited conditions, and behavior-related vulnerabilities that can change how people live, how families plan, and how doctors think about prevention.

He gives examples of genetic information that can dramatically change outcomes.

One example is Tay-Sachs disease, where sequencing and family planning helped reduce the disease within a generation in Ashkenazi Jewish communities. Cahill argues that similar approaches could be applied to other inherited diseases, including sickle cell disease, if people had better access to information and if society were more willing to have honest conversations about genetics, ancestry, and health.

Another example is APOL1-related kidney disease, which affects many people of West African ancestry and is connected to higher rates of kidney disease in African-American populations. Cahill discusses new drugs being developed for this mutation and believes they could have a major effect on mortality and health outcomes.

He also explains how genetics and behavior interact.

Some people may carry one copy of a genetic variant that is not harmful by itself, but becomes dangerous when combined with behaviors like smoking or drinking. He uses alpha-1 antitrypsin as an example, explaining that people who know they carry certain variants may change their behavior immediately to avoid disease.

That is why Cahill believes patient autonomy matters.

He argues that people should control their own health data, medical records, and genetic information. In his view, the more people understand about themselves, the more likely they are to take ownership of their health. He also questions why hospitals and healthcare systems make it so difficult for patients to access their own records.

The conversation also touches on artificial intelligence.

Cahill is careful not to overstate AI as a magic solution. Instead, he sees large language models as tools that can give patients more autonomy by helping them understand their records, genetics, and medical information. The value is not that AI replaces medicine. The value is that AI can help people organize and interpret information that was previously locked away or difficult to understand.

That shift could change the relationship between patients and healthcare institutions.

If patients can upload their medical records, combine them with genetic information, and better understand their risks, they can become more proactive. Cahill believes this could lead to earlier behavior changes, better prevention, lower costs, and longer lives.

The episode also explores the role of government, the FDA, and healthcare regulation.

Cahill argues that the United States is often reactive rather than proactive in healthcare. He believes the FDA and broader system need to think more seriously about speed, cost, and access. He does not dismiss regulation, but he argues that society has to acknowledge that cost matters because an unaffordable medicine cannot help people at scale.

He also reflects on COVID and vaccine communication.

For Cahill, one mistake was overpromising certainty. He believes people should be given clear risk information and allowed to make choices. Americans value optionality, and trust can be damaged when institutions pretend there is no risk or complexity.

The conversation then moves into global competition.

Cahill believes the United States still has major advantages in science and medicine because of its entrepreneurial culture, transparency, willingness to take risks, and ability to gamble on people. He contrasts that with other countries where failure may be less culturally accepted or where scientific transparency is more limited.

At the same time, he points out that other countries are creating incentives that attract clinical trials, manufacturing, and investment. Australia, for example, has created financial incentives that make it attractive for life sciences companies to conduct work there. Cahill sees that as a reminder that countries compete not only through policy, but through the incentives they offer to builders.

Across the episode, Cahill repeatedly returns to one principle: healthcare needs honest conversations.

Whether the topic is obesity, genetics, ancestry, drug pricing, clinical trials, FDA incentives, patient data, or biotech investing, he believes people have to be willing to ask difficult questions if they want to solve real problems.

For Cahill, the future of medicine will come from giving people more information, lowering the cost of transformative therapies, building companies around real patient impact, and understanding that the answers to many diseases may already exist inside human genetics and medical records.

What makes this episode relevant

This episode is relevant because healthcare is facing a collision between science, cost, data, prevention, and access.

Dr. Thomas Cahill’s perspective is unusual because he sits at the intersection of medicine, science, investing, company creation, and public health. He is not only asking whether a drug can work. He is asking whether it can reach people, whether it can be manufactured affordably, whether it can change behavior, and whether it can improve outcomes at scale.

That distinction matters.

Modern healthcare has produced extraordinary science, but many of the system’s incentives still reward complexity, high pricing, slow access, and reactive care. Cahill argues that the next major shift will come from combining better drugs with lower costs, better data, patient ownership, whole genome sequencing, and more honest conversations about risk.

The episode is also important because it reframes prevention.

Instead of treating prevention as a vague lifestyle category, Cahill connects it to genetics, medical records, family planning, metabolic health, and behavior change. If people know what risks they carry, they can make better choices. If they control their data, they can ask better questions. If they understand their biology, they can act before disease appears.

For investors, founders, physicians, policymakers, and anyone interested in the future of healthcare, this conversation offers a clear lesson: scientific breakthroughs are not enough. The system also has to solve for access, affordability, transparency, and trust.

It also shows why difficult conversations matter.

Topics like obesity, genetics, ancestry, drug pricing, health inequality, and patient autonomy can be uncomfortable. But avoiding them does not help patients. Cahill’s view is that more information, handled responsibly, gives people more power over their own lives.

In a healthcare system where records are hard to access, sequencing is underused, and costs remain out of reach for many patients, this episode makes a strong case for a different future: one where people understand their risks, own their data, and benefit from medicines that are built to be both transformative and accessible.

Watch the full episode to hear Dr. Thomas Cahill discuss Newpath Partners, GLP-1 drugs, whole genome sequencing, patient data, biotech investing, drug pricing, and why the future of healthcare may depend on giving people more control over their own information.